Sunday, July 6, 2025 7/6/2025

Cell-Mediated Targeted Redox Intervention for the Treatment and Prevention of Atherosclerosis

Award Number: K01HL145354
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 12/15/2019
PERIOD OF PERFORMANCE END DATE: 11/30/2023

Group Awards By:

View Award Description

Cell-Mediated Targeted Redox Intervention for the Treatment and Prevention of Atherosclerosis - Abstract I, Dr. Edward Bahnson, am a tenure-track assistant professor at the Department of Surgery at UNC. I have a solid training in redox and vascular biology. I spent my post-doctoral training at the Vascular Surgery Divisions at Northwestern University, where I gained further experience in translational research, and vascular biology. Although I have a strong foundation, I require more training to ensure his development into a highly successful independent researcher focusing on translational therapies for vascular disease. The overall goal of this application is to provide me with precisely those skills through mentored and didactic training. Specifically, I will focus on using nanotechnology and cell-mediated-based technologies to deliver redox-based therapeutics to the diseased vasculature. This research area addresses key limitations in my previous experience. Particularly the area of cell-mediated delivery and models of atherosclerosis. The training plan will allow mem to pursue new highly novel translational research that is critical as I begin a new career as an Assistant Professor in the Department of Surgery at UNC. To provide this training, I have has developed a comprehensive career development and research plan. I will be mentored by Prof. Alexander Kabanov and co-mentored by Prof. Nobuyo Maeda. As Director of the Center for Nanotechnology in Drug Delivery, Dr. Kabanov an expert in nanoparticle design and characterization and the use of immune cells as delivery vehicles to sites of inflammation. Dr. Nobuyo Maeda is the Robert H. Wagner Distinguished Professor of Pathology and Laboratory Medicine. She is an expert in molecular genetics, and the creator of the apoE knockout mouse, the first and most robust model of atherosclerosis. In addition to her technical expertise, Dr. Maeda has maintained a vast interest in the training of young scientists. To facilitate his development further, I have established a collaboration with Dr. Elena Batrakova, who has extensive experience in macrophage and macrophage derive exosome-mediated drug delivery. The planned research will couple the power and innovation of nanoparticle delivery of small molecule drugs, with cell-mediated specific targeting. Since I have demonstrated that redox interventions are vasculoprotective in models of restenosis, I propose to use a redox approach as the therapeutic agent in the treatment of atherosclerosis. Specifically, I propose to use the Nrf2 activators to affect the redox status of atherosclerotic arteries locally early as soon as inflammation ensues. I have shown that direct application of the Nrf2 activator Cinnamic Aldehyde, to the vascular wall activates Nrf2, reduces cell proliferation and decreases oxidative stress. This suggests that targeted administration of Nrf 2 activators is vasculoprotective and will decrease redox dysfunction in atherosclerosis. To deliver Nrf2 activators, I will encapsulate the drugs in nanoparticles (NP). I hypothesize that macrophages will take up NP, localize to the atherosclerotic plaque, and deliver redox-based therapeutic interventions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$16 )
2024	2023	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cardiovascular Diseases Research	000	4	4/8/2024	NON-COMPETING CONTINUATION	-$16
														Subtotal = -$16

Issue Date FY: 2023 ( Subtotal = $64,340 )
2023	2023	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cardiovascular Diseases Research	000	4	11/25/2022	NON-COMPETING CONTINUATION	$64,340
														Subtotal = $64,340

Issue Date FY: 2022 ( Subtotal = $154,416 )
2022	2022	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cardiovascular Diseases Research	000	3	12/6/2021	NON-COMPETING CONTINUATION	$154,416
														Subtotal = $154,416

Issue Date FY: 2021 ( Subtotal = $154,416 )
2021	2021	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cardiovascular Diseases Research	000	2	1/13/2021	NON-COMPETING CONTINUATION	$154,416
														Subtotal = $154,416

Issue Date FY: 2020 ( Subtotal = $154,416 )
2020	2020	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cardiovascular Diseases Research	000	1	12/9/2019	NEW	$154,416
														Subtotal = $154,416

Grand Total All Awards = $527,572

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Cell-Mediated Targeted Redox Intervention for the Treatment and Prevention of Atherosclerosis

Award Number: K01HL145354

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 12/15/2019

PERIOD OF PERFORMANCE END DATE: 11/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer